Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ILUSTRO: Zolbetuximab in CLDN18.2 Positive Gastric or GEJ Adenocarcinoma
NCT03505320Phase 2Active, not recruiting
- Sponsor
- Astellas Pharma
- Start
- Jun 2018
- Primary completion
- Jun 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 2, open-label trial of zolbetuximab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (5 cohorts), sponsored by Astellas Pharma. Primary endpoint: Objective Response Rate at 3 months. Started Jun 2018; status: active, not recruiting.
02
Drugs
zolbetuximab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT03505320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03505320.